Cyclacel Pharmaceuticals, Inc. (CYCC) loses confidence of 1 hedge fund managers

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) is on recovery track with 8.97% gain from a 1-year low price of $1.56. The company lost -9.57% to attain the price of $1.7 on Oct. 26, 2017. Throughout the recent session, the prices were hovering between $1.59 and $1.88. These shares are 311.76% off its target price of $7 and the current market capitalization stands at $19.35M. The recent change has given its price a -6.47% deficit over SMA 50 and -84.4% deficit over its 52-week high. The stock witnessed -5.03% declines, 1.8% gains and -68.52% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CYCC’s volatility during a week at 6.86% and during a month it has been found around 6.67%.

Cyclacel Pharmaceuticals, Inc. (CYCC) Top Holders

Institutional investors currently hold around $1 million or 6.4% in CYCC stock. Look at its top three institutional owners. Tang Capital Management Llc owns $1.05 million in Cyclacel Pharmaceuticals, Inc., which represents roughly 5.44% of the company’s market cap and approximately 105.3% of the institutional ownership. Similar statistics are true for the second largest owner, Renaissance Technologies Llc, which owns 48,913 shares of the stock are valued at $92 thousand. The third largest holder is Vanguard Group Inc, which currently holds $73 thousand worth of this stock and that ownership represents nearly 0.38% of its market capitalization.

Cyclacel Pharmaceuticals, Inc. 13F Filings

At the end of 06/30/2017 reporting period, 5 institutional holders increased their position in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) by some 38,107 shares, 6 decreased positions by 216,852 and 4 held positions by 483,657. That puts total institutional holdings at 738,616 shares, according to SEC filings. The stock grabbed 3 new institutional investments totaling 35,692 shares while 1 institutional investors sold out their entire positions totaling 833 shares.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Insider Trades

Multiple company employees have indulged in significant insider trading. Cyclacel Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Eastern Capital Ltd has acquired 850,000 shares of Cyclacel Pharmaceuticals, Inc. (CYCC) in trading session dated Jul. 19, 2017. These shares are worth $1,700,000 and were traded at $2 each. The SEC filing shows that Tang Kevin C performed a purchase of 134,200 shares. The 10% Owner added these shares by way of transaction on Feb. 23, 2017. The company’s shares were assimilated at $4.34 per share worth to an investment of some $582,428 on account of Tang Kevin C.

Director, Barker Sam L, purchased 258 common shares of Cyclacel Pharmaceuticals, Inc. (CYCC) in the open market. In a transaction dated Nov. 20, 2014, the shares were bought at an average price of $36, giving away a sum of $9,288. After this purchase, 258 common shares of CYCC are directly owned by the insider, with total stake valued at $439.

In the transaction dated May. 21, 2013, the great number of shares acquired came courtesy the President & C.E.O.; Rombotis Spiro George added a total of 8,333 shares at an average price of $36, amounting to approximately $299,988. The insider now directly owns 22,358 shares worth $38,009.

Previous articleVanguard Group Inc is the second biggest holder of Nutrisystem, Inc. (NTRI)
Next articleVanda Pharmaceuticals Inc. (VNDA) held by 20 SEC 13F Filers